Other headlines:TomoTherapy changes Siemens supply agreementGE strikes PET deal with Brigham and Women’s Johnson joins InSite One
Philips Healthcare escaped the first quarter with a scant 2% decline in revenues compared with the year-earlier period, a slight drop compared with double-digit declines in the company's consumer lifestyle and lighting divisions. The modest size of the drop was achieved largely on the coattails of gains in home healthcare and through sales in emerging markets overseas, especially in Central and Eastern Europe, the Middle East, and India. The company noted lower sales at Imaging Systems, Healthcare Informatics/Patient Monitoring, and Clinical Care Systems. Chief Executive Gerard Kleisterlee said the company's healthcare group is facing a very soft U.S. hospital market but will continue "to execute its strategy to further build leadership in Health and Well-being, maintaining investments in R&D, marketing, and small acquisitions."
On April 10, 2009, TomoTherapy amended its manufacture and supply agreement with Siemens for the manufacture, purchase, and sale of linear accelerators and related components. The amendment, which itself took effect April 1, 2009, but extends retroactively to Oct. 8, 2008, cuts the maximum price that Siemens can charge TomoTherapy to repair out-of-warranty linear accelerator assemblies. The amendment also provides that if a linear accelerator assembly cannot be repaired, as determined by both Siemens and TomoTherapy, then Siemens will issue a specified credit for the scrap value of the material. It adds to the warranty provision that repaired out-of-warranty accelerator assemblies are warranted for 12 months from the date of delivery.
GE Healthcare has signed a research agreement with Brigham and Women's Hospital to transition PET developments into clinical applications. Staff from GE and the 777-bed teaching affiliate of Harvard Medical School plan to focus on developing personalized approaches to the diagnosis and management of patients with oncologic, neurologic, and cardiovascular diseases.
Douglas L. Johnson has joined InSite One as director of enterprise storage solutions. Johnson, who has 30 years' experience in sales and marketing, will focus on integrated delivery networks and large hospitals whose requirements are addressed by InSite One's InDex enterprise archive and storage consolidation technologies.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.